Discovery of Aloperine as a Potential Antineoplastic Agent for Cholangiocarcinoma Harboring Mutant IDH1
Abstract
:1. Introduction
2. Results
2.1. The Antitumor Activities of Quinolizidine Alkaloids against ICC Cells
2.2. Metabolomics Analysis of ICC Cells Treated with Aloperine
2.3. D-2HG Is Involved in the Antitumor Activity of Aloperine against RBE Cells
2.4. IDH1/2 Mutation Sensitizes Cells to Aloperine
2.5. Aloperine Reduced D-2HG Levels in RBE Cells by Decreasing Glutamate
2.6. Aloperine Preferentially Resensitizes RBE Cells to 5-Fluorouracil, AGI-5198 and Olaparib
3. Discussion
4. Materials and Methods
4.1. Reagents
4.2. Cell Culture
4.3. Plasmid Construction
4.4. Lentivirus Infection and Stable Cell-Line Generation
4.5. In Vitro Antitumor Assay
4.6. Synergy and Antagonism Analysis
4.7. Preparation of Cellular Metabolites
4.8. Metabolomics Analysis and Data Processing and Analysis
4.9. Quantification Analysis of D-2HG, Glutamate and Glutamine
4.10. Western Blotting
4.11. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
References
- Moris, D.; Palta, M.; Kim, C.; Allen, P.J.; Morse, M.A.; Lidsky, M.E. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA-Cancer J. Clin. 2022, 73, 198–222. [Google Scholar] [CrossRef] [PubMed]
- Zeng, J.T.; Zhang, J.F.; Wang, Y.; Qing, Z.; Luo, Z.H.; Zhang, Y.L.; Zhang, Y.; Luo, X.Z. Intrahepatic cholangiocarcinoma is more complex than we thought: A case report. World J. Clin. Cases 2021, 9, 1469–1474. [Google Scholar] [CrossRef] [PubMed]
- Ruff, S.M.; Diaz, D.A.; Pitter, K.L.; Hartwell, B.C.; Pawlik, T.M. Multidisciplinary management in the treatment of intrahepatic cholangiocarcinoma. CA-Cancer J. Clin. 2023, 73, 346–352. [Google Scholar] [CrossRef]
- Becht, R.; Wasilewicz, M.P. New options for systemic therapies in intrahepatic cholangiocarcinoma (iCCA). Med. Lith. 2023, 59, 1174. [Google Scholar] [CrossRef] [PubMed]
- Storandt, M.H.; Kurniali, P.C.; Mahipal, A.; Jin, Z. Targeted therapies in advanced cholangiocarcinoma. Life 2023, 13, 2066. [Google Scholar] [CrossRef]
- Lyu, J.; Liu, Y.; Gong, L.; Chen, M.; Madanat, Y.F.; Zhang, Y.; Cai, F.; Gu, Z.; Cao, H.; Kaphle, P.; et al. Disabling uncompetitive inhibition of oncogenic IDH mutations drives acquired resistance. Cancer Discov. 2023, 13, 170–193. [Google Scholar] [CrossRef]
- Subbiah, V.; Sahai, V.; Maglic, D.; Bruderek, K.; Touré, B.B.; Zhao, S.; Valverde, R.; O’Hearn, P.J.; Moustakas, D.T.; Schönherr, H.; et al. RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations. Cancer Discov. 2023, 13, 2012–2031. [Google Scholar] [CrossRef]
- Waitkus, M.S.; Diplas, B.H.; Yan, H. Biological role and therapeutic potential of IDH mutations in cancer. Cancer Cell 2018, 34, 186–195. [Google Scholar] [CrossRef]
- Wang, P.; Wu, J.; Ma, S.; Zhang, L.; Yao, J.; Hoadley, K.A.; Wilkerson, M.D.; Perou, C.M.; Guan, K.L.; Ye, D.; et al. Oncometabolite D-2-hydroxyglutarate inhibits ALKBH DNA repair enzymes and sensitizes IDH mutant cells to alkylating agents. Cell Rep. 2015, 13, 2353–2361. [Google Scholar] [CrossRef]
- Saha, S.K.; Gordan, J.D.; Kleinstiver, B.P.; Vu, P.; Najem, M.S.; Yeo, J.C.; Shi, L.; Kato, Y.; Levin, R.S.; Webber, J.T.; et al. Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma. Cancer Discov. 2016, 6, 727–739. [Google Scholar] [CrossRef]
- Furukawa, T.; Tabata, S.; Minami, K.; Yamamoto, M.; Kawahara, K.; Tanimoto, A. Metabolic reprograming of cancer as a therapeutic target. Biochim. Biophys. Acta-Gen. Subj. 2023, 1867, 130301. [Google Scholar] [CrossRef]
- Yang, Z.; Jiang, B.; Wang, Y.; Ni, H.; Zhang, J.; Xia, J.; Shi, M.; Hung, L.M.; Ruan, J.; Mak, T.W.; et al. 2-HG inhibits necroptosis by stimulating DNMT1-dependent hypermethylation of the RIP3 promoter. Cell Rep. 2017, 19, 1846–1857. [Google Scholar] [CrossRef] [PubMed]
- Carbonneau, M.; Gagné, L.M.; Lalonde, M.-E.; Germain, M.-A.; Motorina, A.; Guiot, M.-C.; Secco, B.; Vincent, E.E.; Tumber, A.; Hulea, L.; et al. The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway. Nat. Commun. 2016, 7, 12700. [Google Scholar] [CrossRef] [PubMed]
- Xu, W.; Yang, H.; Liu, Y.; Yang, Y.; Wang, P.; Kim, S.H.; Ito, S.; Yang, C.; Wang, P.; Xiao, M.T.; et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19, 17–30. [Google Scholar] [CrossRef] [PubMed]
- Xu, Q.; Ahmed, A.K.; Zhu, Y.; Wang, K.; Lv, S.; Li, Y.; Jiang, Y. Oncogenic MicroRNA-20a is downregulated by the HIF-1alpha/c-MYC pathway in IDH1 R132H-mutant glioma. Biochem. Biophys. Res. Commun. 2018, 499, 882–888. [Google Scholar] [CrossRef] [PubMed]
- Li, F.; He, X.; Ye, D.; Lin, Y.; Yu, H.; Yao, C.; Huang, L.; Zhang, J.; Wang, F.; Xu, S.; et al. NADP(+)-IDH mutations promote hypersuccinylation that impairs mitochondria respiration and induces apoptosis resistance. Mol. Cell 2015, 60, 661–675. [Google Scholar] [CrossRef]
- Huang, G.H.; Du, L.; Li, N.; Zhang, Y.; Xiang, Y.; Tang, J.H.; Xia, S.; Zhang, E.E.; Lv, S.Q. Methylation-mediated miR-155-FAM133A axis contributes to the attenuated invasion and migration of IDH mutant gliomas. Cancer Lett. 2018, 432, 93–102. [Google Scholar] [CrossRef]
- Borger, D.R.; Tanabe, K.K.; Fan, K.C.; Lopez, H.U.; Fantin, V.R.; Straley, K.S.; Schenkein, D.P.; Hezel, A.F.; Ancukiewicz, M.; Liebman, H.M.; et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012, 17, 72–79. [Google Scholar] [CrossRef]
- Delahousse, J.; Verlingue, L.; Broutin, S.; Legoupil, C.; Touat, M.; Doucet, L.; Ammari, S.; Lacroix, L.; Ducreux, M.; Scoazec, J.Y.; et al. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas. Eur. J. Cancer 2018, 90, 83–91. [Google Scholar] [CrossRef]
- Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J. Nat. Prod. 2020, 83, 770–803. [Google Scholar] [CrossRef]
- Li, Y.; Wang, G.; Liu, J.; Ouyang, L. Quinolizidine alkaloids derivatives from Sophora alopecuroides Linn: Bioactivities, structure-activity relationships and preliminary molecular mechanisms. Eur. J. Med. Chem. 2020, 188, 111972. [Google Scholar] [CrossRef] [PubMed]
- Qiu, G.; Xie, J.; Li, F.; Han, K.; Long, Q.; Kowah, J.A.H.; Gao, R.; Wang, L.; Liu, X. Design, synthesis and biological evaluation of matrine contains benzimidazole derivatives as dual TOPOI and PARP inhibitors for cancer therapy. Eur. J. Med. Chem. 2024, 270, 116348. [Google Scholar] [CrossRef] [PubMed]
- Hu, Z.-X.; Zhang, J.; Zhang, T.; Tian, C.-Y.; An, Q.; Yi, P.; Yuan, C.-M.; Zhang, Z.-K.; Zhao, L.-H.; Hao, X.-J. Aloperine-type alkaloids with antiviral and antifungal activities from the seeds of Sophora alopecuroides L. J. Agric. Food Chem. 2024, 72, 8225–8236. [Google Scholar] [CrossRef] [PubMed]
- Kowah, J.A.H.; Gao, R.; Li, F.; Guang, C.; Jiang, M.; Wu, X.; Wang, L.; Liu, X. Matrine family derivatives: Synthesis, reactions procedures, mechanism, and application in medicinal, agricultural, and materials chemistry. Eur. J. Med. Chem. Rep. 2023, 7, 100098. [Google Scholar] [CrossRef]
- Wang, R.; Deng, X.; Gao, Q.; Wu, X.; Han, L.; Gao, X.; Zhao, S.; Chen, W.; Zhou, R.; Li, Z.; et al. Sophora alopecuroides L.: An ethnopharmacological, phytochemical, and pharmacological review. J. Ethnopharmacol. 2020, 248, 112172. [Google Scholar] [CrossRef]
- Cely-Veloza, W.; Kato, M.J.; Coy-Barrera, E. Quinolizidine-type alkaloids: Chemodiversity, occurrence, and bioactivity. ACS Omega 2023, 8, 27862–27893. [Google Scholar] [CrossRef]
- Yang, Y.; Sun, M.; Yao, W.; Wang, F.; Li, X.; Wang, W.; Li, J.; Gao, Z.; Qiu, L.; You, R.; et al. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib. J. Immunother. Cancer 2020, 8, e000317. [Google Scholar] [CrossRef]
- Zhang, L.; Li, R.J.; Zheng, T.; Wu, H.; Yin, Y.Y. An integrated analytical strategy to decipher the metabolic profile of alkaloids in Compound Kushen injection based on UHPLC-ESI-QTOF/MS. Xenobiotica 2023, 53, 248–259. [Google Scholar] [CrossRef]
- Yang, N.M.; Han, F.; Cui, H.; Huang, J.X.; Wang, T.; Zhou, Y.; Zhou, J.X. Matrine suppresses proliferation and induces apoptosis in human cholangiocarcinoma cells through suppression of JAK2/STAT3 signaling. Pharmacol. Rep. 2015, 67, 388–393. [Google Scholar] [CrossRef]
- Zhang, Z.P.; Wang, X.F.; Wu, W.G.; Wang, J.W.; Wang, Y.; Wu, X.S.; Fei, X.Z.; Li, S.G.; Zhang, J.; Dong, P.; et al. Effects of matrine on proliferation and apoptosis in gallbladder carcinoma cells (GBC-SD). Phytother. Res. 2012, 26, 932–937. [Google Scholar] [CrossRef]
- Zhang, Y.B.; Luo, D.; Yang, L.; Cheng, W.; He, L.J.; Kuang, G.K.; Li, M.M.; Li, Y.L.; Wang, G.C. Matrine-type alkaloids from the roots of and their antiviral activities against the hepatitis B virus. J. Nat. Prod. 2018, 81, 2259–2265. [Google Scholar] [CrossRef] [PubMed]
- Li, G.; Lu, J.; Wang, C.; Chang, X.; Qu, Z.; Zhang, W.; Zhuang, C.; Miao, Z.; Xu, W. Discovery of sophoridine α-aryl propionamide derivative ZM600 as a novel antihepatic fibrosis agent. J. Med. Chem. 2024, 67, 11389–11400. [Google Scholar] [CrossRef] [PubMed]
- Salamanca-Cardona, L.; Shah, H.; Poot, A.J.; Correa, F.M.; Di Gialleonardo, V.; Lui, H.; Miloushev, V.Z.; Granlund, K.L.; Tee, S.S.; Cross, J.R.; et al. In vivo imaging of glutamine metabolism to the oncometabolite 2-hydroxyglutarate in IDH1/2 mutant tumors. Cell Metab. 2017, 26, 830–841.e3. [Google Scholar] [CrossRef] [PubMed]
- Bianchi, M.G.; Bardelli, D.; Chiu, M.; Bussolati, O. Changes in the expression of the glutamate transporter EAAT3/EAAC1 in health and disease. Cell. Mol. Life Sci. 2014, 71, 2001–2015. [Google Scholar] [CrossRef] [PubMed]
- Lu, C.; Ward, P.S.; Kapoor, G.S.; Rohle, D.; Turcan, S.; Abdel-Wahab, O.; Edwards, C.R.; Khanin, R.; Figueroa, M.E.; Melnick, A.; et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483, 474–478. [Google Scholar] [CrossRef]
- Borger, D.R.; Goyal, L.; Yau, T.; Poon, R.T.; Ancukiewicz, M.; Deshpande, V.; Christiani, D.C.; Liebman, H.M.; Yang, H.; Kim, H.; et al. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin. Cancer Res. 2014, 20, 1884–1890. [Google Scholar] [CrossRef]
- Wu, M.-J.; Shi, L.; Dubrot, J.; Merritt, J.; Vijay, V.; Wei, T.-Y.; Kessler, E.; Olander, K.E.; Adil, R.; Pankaj, A.; et al. Mutant IDH inhibits IFNγ–TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma. Cancer Discov. 2022, 12, 812–835. [Google Scholar] [CrossRef]
- Notarangelo, G.; Spinelli, J.B.; Perez, E.M.; Baker, G.J.; Kurmi, K.; Elia, I.; Stopka, S.A.; Baquer, G.; Lin, J.R.; Golby, A.J.; et al. Oncometabolite D-2HG alters T cell metabolism to impair CD8(+) T cell function. Science 2022, 377, 1519–1529. [Google Scholar] [CrossRef]
- Ward, P.S.; Patel, J.; Wise, D.R.; Abdel-Wahab, O.; Bennett, B.D.; Coller, H.A.; Cross, J.R.; Fantin, V.R.; Hedvat, C.V.; Perl, A.E.; et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17, 225–234. [Google Scholar] [CrossRef]
- McBrayer, S.K.; Mayers, J.R.; DiNatale, G.J.; Shi, D.D.; Khanal, J.; Chakraborty, A.A.; Sarosiek, K.A.; Briggs, K.J.; Robbins, A.K.; Sewastianik, T.; et al. Transaminase inhibition by 2-hydroxyglutarate impairs glutamate biosynthesis and redox homeostasis in glioma. Cell 2018, 175, 101–116.e25. [Google Scholar] [CrossRef]
- Seltzer, M.J.; Bennett, B.D.; Joshi, A.D.; Gao, P.; Thomas, A.G.; Ferraris, D.V.; Tsukamoto, T.; Rojas, C.J.; Slusher, B.S.; Rabinowitz, J.D.; et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010, 70, 8981–8987. [Google Scholar] [CrossRef] [PubMed]
- Elhammali, A.; Ippolito, J.E.; Collins, L.; Crowley, J.; Marasa, J.; Piwnica-Worms, D. A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor. Cancer Discov. 2014, 4, 828–839. [Google Scholar] [CrossRef] [PubMed]
- Pirozzi, C.J.; Yan, H. The implications of IDH mutations for cancer development and therapy. Nat. Rev. Clin. Oncol. 2021, 18, 645–661. [Google Scholar] [CrossRef]
- Harding, J.J.; Lowery, M.A.; Shih, A.H.; Schvartzman, J.M.; Hou, S.; Famulare, C.; Patel, M.; Roshal, M.; Do, R.K.; Zehir, A.; et al. Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition. Cancer Discov. 2018, 8, 1540–1547. [Google Scholar] [CrossRef] [PubMed]
- Cleary, J.M.; Rouaisnel, B.; Daina, A.; Raghavan, S.; Roller, L.A.; Huffman, B.M.; Singh, H.; Wen, P.Y.; Bardeesy, N.; Zoete, V.; et al. Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma. npj Precis. Oncol. 2022, 6, 61. [Google Scholar] [CrossRef] [PubMed]
- Lamarca, A.; Barriuso, J.; McNamara, M.G.; Valle, J.W. Molecular targeted therapies: Ready for “prime time” in biliary tract cancer. J. Hepatol. 2020, 73, 170–185. [Google Scholar] [CrossRef]
- Yao, K.; Liu, H.; Yin, J.; Yuan, J.; Tao, H. Synthetic lethality and synergetic effect: The effective strategies for therapy of IDH-mutated cancers. J. Exp. Clin. Cancer Res. 2021, 40, 263. [Google Scholar] [CrossRef]
- Telaglenastat with Radiation Therapy and Temozolomide in Treating Patients with IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma. Available online: https://clinicaltrials.gov/study/NCT03528642 (accessed on 18 August 2024).
- Study of Olaparib and Durvalumab in IDH-mutated Solid Tumors (SOLID). Available online: https://clinicaltrials.gov/study/NCT03991832?cond=Cholangiocarcinoma&term=IDH&rank=1 (accessed on 18 August 2024).
- Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors. Available online: https://clinicaltrials.gov/study/NCT03878095?cond=Cholangiocarcinoma&term=IDH&rank=4 (accessed on 18 August 2024).
- Jiang, B.; Zhao, W.; Shi, M.; Zhang, J.; Chen, A.; Ma, H.; Suleman, M.; Lin, F.; Zhou, L.; Wang, J.; et al. IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53. J. Biol. Chem. 2018, 293, 9747–9758. [Google Scholar] [CrossRef]
- Wu, X.K.; Lu, Y.F.; Qin, X.M. Combination of Compound Kushen Injection and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis. J. Ethnopharmacol. 2022, 283, 114690. [Google Scholar] [CrossRef]
- Cao, J.H.; Wu, X.K.; Qin, X.M.; Li, Z.Y. Uncovering the effect of passage number on HT29 cell line based on the cell metabolomic approach. J. Proteome Res. 2021, 20, 1582–1590. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wu, X.; Li, Y.; Han, C.; Li, S.; Qin, X. Discovery of Aloperine as a Potential Antineoplastic Agent for Cholangiocarcinoma Harboring Mutant IDH1. Int. J. Mol. Sci. 2024, 25, 9226. https://doi.org/10.3390/ijms25179226
Wu X, Li Y, Han C, Li S, Qin X. Discovery of Aloperine as a Potential Antineoplastic Agent for Cholangiocarcinoma Harboring Mutant IDH1. International Journal of Molecular Sciences. 2024; 25(17):9226. https://doi.org/10.3390/ijms25179226
Chicago/Turabian StyleWu, Xingkang, Yang Li, Chenchen Han, Shifei Li, and Xuemei Qin. 2024. "Discovery of Aloperine as a Potential Antineoplastic Agent for Cholangiocarcinoma Harboring Mutant IDH1" International Journal of Molecular Sciences 25, no. 17: 9226. https://doi.org/10.3390/ijms25179226